Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
0.9963
-0.0137 (-1.36%)
At close: Jun 12, 2026, 4:00 PM EDT
1.050
+0.054 (5.39%)
After-hours: Jun 12, 2026, 7:59 PM EDT

John Keells Holdings Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
5.495.014.434.515.495.04
Research & Development
4.584.063.554.155.386.91
Total Operating Expenses
10.079.077.988.6610.8611.95
Operating Income
-10.07-9.07-7.98-8.66-10.86-11.95
Other Non-Operating Income (Expense)
0.20.16-7.068.540.03-0.04
Total Non-Operating Income (Expense)
0.20.16-7.068.540.03-0.04
Pretax Income
-9.87-8.91-15.04-0.12-10.83-11.99
Net Income
-9.87-8.91-15.04-0.12-10.83-11.99
Net Income Attributable to Preferred Dividends
11.635.95----
Net Income to Common
-21.5-14.87-15.04-0.12-10.83-11.99
Shares Outstanding (Basic)
110000
Shares Outstanding (Diluted)
110000
Shares Change (YoY)
4128.17%4243.28%1103.96%214.03%672.09%309.60%
EPS (Basic)
-39.48-23.95-1052.16-101.28-28646.40-244800.00
EPS (Diluted)
-39.48-23.95-1052.16-101.28-28646.40-244800.00
Free Cash Flow
-8.76-8.27-18.34-7.29-11.22-11.22
Free Cash Flow Per Share
-6.27-13.32-1283.18-6137.54-29677.30-229198.00
EBITDA
-10.04-9.04-7.95-8.63-10.84-11.93
EBIT
-10.07-9.07-7.98-8.66-10.86-11.95
SEC Filings: 10-K · 10-Q